Societal CDMO Inc
F:RAH
Societal CDMO Inc
F:RAH
Price:
1.58
EUR
Market Closed
Market Cap:
€165.5m
Relative Value
There is not enough data to reliably calculate the relative value of RAH.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RAH
Relative Value
Base Case
Not Available
Multiples Across Competitors
RAH Competitors Multiples
Societal CDMO Inc Competitors
Societal CDMO Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Societal CDMO Inc
F:RAH
|
165.7m EUR | 2.1 | -14.7 | 35.2 | -52.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD | 15.1 | 47.7 | 32.2 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD | 6.2 | 21.9 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF | 4.7 | 30.5 | 12.9 | 15 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP | 5.5 | 31.3 | 17.3 | 24.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF | 5.5 | 22 | 13.6 | 17.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.5 | 9.9 | 11.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD | 2.6 | 17.5 | 6.8 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
